|
Apr 7
|
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
|
|
Apr 4
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Apr 3
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Mar 12
|
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?
|
|
Mar 11
|
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
|
|
Mar 10
|
Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
|
|
Mar 10
|
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
|
|
Mar 10
|
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
|
|
Mar 1
|
Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?
|
|
Feb 28
|
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
|
|
Feb 28
|
High Growth Tech Stocks to Watch in US Market February 2025
|
|
Feb 25
|
Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery
|
|
Feb 21
|
Incyte and Genesis collaborate on small-molecule medicines
|
|
Feb 20
|
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
|
|
Feb 18
|
Incyte Stock Sees Relative Strength Rating Rise To 71
|
|
Feb 18
|
Incyte to Present at Upcoming Investor Conferences
|
|
Feb 17
|
3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value
|
|
Feb 11
|
Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 11
|
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook
|
|
Feb 11
|
Q4 2024 Incyte Corp Earnings Call
|